Shandong Xinhua (00719) obtained the registration certificate for Glucosamine Sulfate Capsules.

SHANDONG XINHUA (00719) announces that recently, Shandong Xinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Shandong Xinhua Pharmaceutical" or "the Company") has received the approval and issuance of the Drug Registration Certificate for Glucosamine Sulfate Capsules (hereinafter referred to as "the Product") from the National Medical Products Administration. In August 2024, Shandong Xinhua Pharmaceutical submitted the application for market authorization registration of Glucosamine Sulfate Capsules to the Center for Drug Evaluation of the National Medical Products Administration (CDE) and received acceptance. In February 2026, it obtained the Drug Registration Certificate, with the evaluation conclusion being approval for registration. The Product is mainly used clinically for the treatment of primary and secondary osteoarthritis. The Product belongs to Category B of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025)." According to relevant statistics, the sales of Glucosamine Sulfate Capsules in public medical institutions in China in 2024 were approximately 850 million RMB.